Single-Dose Administration of ABVD Through Peripheral IV
Yes, it is acceptable to administer one dose of doxorubicin, bleomycin, and dacarbazine through a peripheral intravenous (PIV) line, but doxorubicin requires specific precautions due to its vesicant properties.
Key Considerations by Agent
Doxorubicin (Vesicant)
Doxorubicin is classified as a vesicant agent that can cause severe tissue necrosis if extravasation occurs 1. However, the FDA-approved administration includes intravenous delivery 2, and the ESMO Hodgkin lymphoma guidelines routinely specify i.v. administration as standard practice 3.
Critical safety measures for PIV administration:
- Ensure excellent venous access with a well-functioning, recently placed PIV in a large vein
- Administer slowly over 10 minutes with continuous monitoring 2
- Verify blood return before, during, and after administration
- Never apply manual pressure over suspected extravasation sites 1
- Have dexrazoxane immediately available (must be given within 6 hours if extravasation occurs) 1
Bleomycin (Non-vesicant)
Bleomycin may be given intravenously, intramuscularly, or subcutaneously 4. The FDA label specifies IV administration should be done "slowly over a period of 10 minutes" 4. This agent poses minimal extravasation risk and is safe through PIV.
Dacarbazine (Irritant)
Dacarbazine is an irritant rather than a vesicant, making it safer for PIV administration 3. While it can cause local discomfort if extravasated, it does not typically cause tissue necrosis.
Clinical Practice Evidence
Real-world data demonstrates that ABVD is routinely administered in community settings through peripheral access. A 2025 retrospective study of 69 patients receiving ABVD at Harbor-UCLA Medical Center showed excellent outcomes with 78.3% complete response rate and 95.4% 5-year overall survival 5. The standard ABVD regimen specifies i.v. administration on days 1 and 15 of each cycle 3.
Practical Algorithm for PIV Use
Proceed with PIV if:
- Large-bore catheter (20-gauge or larger) in good position
- Excellent blood return confirmed
- No history of difficult venous access
- Single cycle planned (not multiple consecutive days)
- Staff trained in extravasation management present
Consider central access instead if:
- Poor peripheral venous access
- History of multiple PIV failures
- Patient anxiety about peripheral access
- Multiple consecutive treatment days planned
- Cumulative doxorubicin doses approaching 400 units (though this applies to long-term therapy, not single doses) 3
Extravasation Management Preparedness
If administering through PIV, ensure immediate availability of:
- Dexrazoxane for anthracycline extravasation (1000 mg/m² within 6 hours, then 1000 mg/m² day 2, then 500 mg/m² day 3) 1
- Cold compresses (for doxorubicin extravasation) 1
- Equipment to aspirate extravasated drug through the existing cannula 1
Common pitfall: Do not apply DMSO if dexrazoxane will be used for anthracycline extravasation, and remove ice packs 15 minutes before dexrazoxane administration 1.
Bottom Line
Single-dose ABVD administration through PIV is standard practice and safe when proper precautions are followed, particularly ensuring excellent venous access and immediate extravasation management capability. The vesicant nature of doxorubicin requires vigilance, but does not preclude peripheral administration for single doses in patients with good venous access 3, 1, 4, 2.